MedPath

Evaluation the possible side effects of rivaroxaban in patients with pulmonary valve replacement or Fontan surgery.

Phase 4
Recruiting
Conditions
Patients who have undergone pulmonary valve replacement and Fontan surgery..
Other congenital malformations of cardiac chambers and connections
q20.8
Registration Number
IRCT20220516054868N2
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
75
Inclusion Criteria

Obtaining informed consent (patient or parents)
Age 5-18 years old
Performed pulmonary valve replacement or Fontan surgery

Exclusion Criteria

Intolerance or sensitivity to warfarin
Intolerance or sensitivity to rivaroxaban

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Major and minor bleeding. Timepoint: 3-6 months. one year. Method of measurement: questionnaire-The tool does not have a specific measurement and is descriptive.;Stroke. Timepoint: 3-6 months. one year. Method of measurement: questionnaire-The tool does not have a specific measurement and is descriptive.;Thromboembolic events. Timepoint: 3-6 months. one year. Method of measurement: questionnaire-The tool does not have a specific measurement and is descriptive.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath